Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02183753 · ClinicalTrials.gov registry record · Early Phase 1
Effects of Wood Smoke Particles on Influenza-induced Nasal Inflammation in Normal Volunteers
A Early Phase 1 study, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 39
- Enrollment target
NCT02183753: Completed Early Phase 1 study, sponsored by University of North Carolina, Chapel Hill.
NCT02183753 is a Early Phase 1 study that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 39 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (26% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02183753, a Early Phase 1 study, has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 39 participants
- Enrollment target
Study Summary
This study is focused on the pathophysiology underlying the association between exposure to particulate pollutants and risk for/response to viral infection. The investigators hypothesize that exposure to wood smoke particles (WSP) enhances influenza virus-induced granulocyte and NK cell activation, via hyaluronic acid-mediated effects on IFNg production. Oxidant stress and viral replication may also be affected. As an NIH funded ViCTER project, the purpose of the study is also to test novel assays of granulocyte activation (Doershuk lab) and lipid mediator activation (Albritton lab) which have not previously been used in this type of research. Healthy, nonsmoking adults age 18-40 years will be recruited. This is a randomized, placebo controlled study comparing NLF granulocyte responses to LAIV administered after either WSP or clean air, in normal healthy volunteers. Subjects receive either WSP or placebo (clean air), followed by a standardized dose of LAIV and serial post-infection sampling of nasal lavage fluids, nasal biopsy and blood
Primary Outcome
Change in IL-13 and ECP in nasal lavage fluids (NLF) compared to pre-virus baseline
Interventions
- OTHER wood smoke
- OTHER clean air
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2014-07 |
| Est. Completion | 2015-04 |
| Phase | Early Phase 1 |
What the finished NCT02183753 record still lists
NCT02183753 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 39 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (26% lower).
The record links to 0 conditions, and to 2 interventions - of which wood smoke is the first listed.
NCT02183753 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02183753 about?
NCT02183753 is a clinical study titled "Effects of Wood Smoke Particles on Influenza-induced Nasal Inflammation in Normal Volunteers". This study is focused on the pathophysiology underlying the association between exposure to particulate pollutants and risk for/response to viral infection. The investigators hypothesize that exposure to wood smoke particles (WSP) enhances influenza virus-induced granulocyte and NK cell activation, ...
What is the current status of trial NCT02183753?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 39 participants. The study started on 2014-07. Estimated completion is 2015-04.
What interventions are being tested in trial NCT02183753?
The interventions under investigation include: wood smoke (OTHER), clean air (OTHER).
Who is sponsoring clinical trial NCT02183753?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02183753's enrollment target sits among peer trials
39 689th of 2000 higher than 1,303 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03465592 · 39 participants · Phase 1
Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
- NCT03961776 · 39 participants
Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems
- NCT04050280 · 39 participants · Phase 2
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
- NCT04190862 · 39 participants · Phase 1
E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia